These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 39234842)

  • 1. Pembrolizumab-induced autoimmune encephalitis in a woman with lentiginous melanoma.
    Omizzolo L
    Emergencias; 2024 Jun; 36(4):319. PubMed ID: 39234842
    [No Abstract]   [Full Text] [Related]  

  • 2. Pembrolizumab-Induced Alopecia Areata.
    Elshimy N; Blakeway E; Mitra A
    Skinmed; 2019; 17(2):142-143. PubMed ID: 31145074
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute localised exanthematous pustulosis secondary to pembrolizumab.
    Wang CY; Khoo C; McCormack CJ; Xu W; Pan Y
    Australas J Dermatol; 2017 Nov; 58(4):322-323. PubMed ID: 28691194
    [No Abstract]   [Full Text] [Related]  

  • 4. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
    Arianayagam S; Ieremia E; Matin RN
    Eur J Dermatol; 2019 Jun; 29(3):349-351. PubMed ID: 31389799
    [No Abstract]   [Full Text] [Related]  

  • 5. A case of ruptured hepatic metastases during pembrolizumab administration for cutaneous malignant melanoma.
    Igari S; Yamamoto M; Kikuchi N; Ohtsuka M; Yamamoto T
    An Bras Dermatol; 2024; 99(3):450-451. PubMed ID: 38307808
    [No Abstract]   [Full Text] [Related]  

  • 6. Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment.
    Nardin C; Pelletier F; Puzenat E; Aubin F
    Acta Derm Venereol; 2019 Sep; 99(10):913-914. PubMed ID: 31017249
    [No Abstract]   [Full Text] [Related]  

  • 7. Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma.
    Sanchez A; Montaudie H; Bory P; Belgodere X; Passeron T; Lacour JP; Picard A
    JAMA Dermatol; 2018 Nov; 154(11):1354-1356. PubMed ID: 30326507
    [No Abstract]   [Full Text] [Related]  

  • 8. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
    Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
    Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treating metastatic melanoma: Risk management].
    Lebbe C; Robert C
    Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
    [No Abstract]   [Full Text] [Related]  

  • 10. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
    Earl DE; Loochtan AI; Bedlack RS
    Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
    [No Abstract]   [Full Text] [Related]  

  • 11. Fulminant type 1 diabetes mellitus associated with pembrolizumab.
    Mizab Mellah C; Sánchez Pérez M; Santos Rey MD; Hernández García M
    Endocrinol Diabetes Nutr; 2017 May; 64(5):272-273. PubMed ID: 29056250
    [No Abstract]   [Full Text] [Related]  

  • 12. Birdshot-like Chorioretinopathy Associated With Pembrolizumab Treatment.
    Acaba-Berrocal LA; Lucio-Alvarez JA; Mashayekhi A; Ho AC; Dunn JP; Shields CL
    JAMA Ophthalmol; 2018 Oct; 136(10):1205-1207. PubMed ID: 30054605
    [No Abstract]   [Full Text] [Related]  

  • 13. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
    Berger M; Legeay AL; Souci S; Streichenberger N; Thomas L; Dalle S
    Eur J Cancer; 2018 Nov; 104():227-230. PubMed ID: 30322679
    [No Abstract]   [Full Text] [Related]  

  • 14. Autoimmune Encephalitis following Checkpoint Inhibitor Therapy in a Patient with Metastatic Melanoma in Complete Remission.
    Civardi G; Medioli A; Braghieri C; Ambroggi M; Immovilli P; Orsucci S; Contini P; Aronica G; Cavanna L
    Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia.
    Berger M; Amini-Adlé M; Crumbach L; Paubelle E; Dalle S
    Eur J Cancer; 2019 Mar; 110():49-52. PubMed ID: 30739840
    [No Abstract]   [Full Text] [Related]  

  • 16. Lichen planus in a patient treated with pembrolizumab for metastatic malignant melanoma.
    Denny J; Chong H; Akhras V
    Clin Exp Dermatol; 2018 Apr; 43(3):354-356. PubMed ID: 29222829
    [No Abstract]   [Full Text] [Related]  

  • 17. [Grover's-like drug eruption under anti-PD-1 therapy for metastatic melanoma].
    Amini-Adle M; Balme B; Dalle S
    Ann Dermatol Venereol; 2018 Dec; 145(12):802-803. PubMed ID: 30415933
    [No Abstract]   [Full Text] [Related]  

  • 18. Pembrolizumab (Keytruda°) and metastatic or inoperable melanoma.
    Prescrire Int; 2017 May; 26(182):118-119. PubMed ID: 30730667
    [No Abstract]   [Full Text] [Related]  

  • 19. Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae.
    Donaldson M; Owen JL; Choi JN
    JAMA Dermatol; 2018 Jul; 154(7):846-847. PubMed ID: 29800007
    [No Abstract]   [Full Text] [Related]  

  • 20. Generalized morphea in the setting of pembrolizumab.
    Cheng MW; Hisaw LD; Bernet L
    Int J Dermatol; 2019 Jun; 58(6):736-738. PubMed ID: 29931792
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.